|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Zhang S, Zhao P, Zeng H
and Zou X: Report of cancer incidence and mortality in China, 2010.
Ann Transl Med. 2:612014.PubMed/NCBI
|
|
3
|
Chen WQ, Zheng RS, Zhang SW, Zeng HM and
Zou XN: The incidences and mortalities of major cancers in China,
2010. Chin J Cancer. 33:402–405. 2014.PubMed/NCBI
|
|
4
|
McKee MD, Bondarenko I, Guclu SZ, et al:
Veliparib (ABT-888) or placebo combined with carboplatin and
paclitaxel in patients with previously untreated
advanced/metastatic squamous (Sq) non-small cell lung cancer
(NSCLC): A randomized phase 3 trial. ASCO Annual Meeting
Proceedings. pp. TPS8107Chicago, IL: 2015
|
|
5
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ettinger DS, Akerley W, Borghaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK,
Govindan R, et al: Non-small cell lung cancer. J Natl Compr Canc
Netw. 10:1236–1271. 2012.PubMed/NCBI
|
|
7
|
Li H, Chen SJ, Chen YF, Meng QC, Durand J,
Oparil S and Elton TS: Enhanced endothelin-1 and endothelin
receptor gene expression in chronic hypoxia. J Appl Physiol (1985).
77:1451–1459. 1994.PubMed/NCBI
|
|
8
|
Smith TG, Robbins PA and Ratcliffe PJ: The
human side of hypoxia-inducible factor. Br J Haematol. 141:325–334.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Parvin A, Pranap R, Shalini U, Devendran
A, Baker JE and Dhanasekaran A: Erythropoietin protects
cardiomyocytes from cell death during hypoxia/reperfusion injury
through activation of survival signaling pathways. PLoS One.
9:e1074532014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang W, Liu X, Cao J, Meng F, Li M, Chen
B and Zhang J: miR-134 regulates ischemia/reperfusion
injury-induced neuronal cell death by regulating CREB signaling. J
Mol Neurosci. 55:821–829. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Simon MC: Abstract IA13: A hypoxic
microenvironment influences pancreatic cancer progression. Cancer
Res. 75:IA13. 2015. View Article : Google Scholar
|
|
12
|
Shay JE, Imtiyaz HZ, Sivanand S, Durham
AC, Skuli N, Hsu S, Mucaj V, Eisinger-Mathason TS, Krock BL,
Giannoukos DN and Simon MC: Inhibition of hypoxia-inducible factors
limits tumor progression in a mouse model of colorectal cancer.
Carcinogenesis. 35:1067–1077. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Amelio I and Melino G: The p53 family and
the hypoxia-inducible factors (HIFs): Determinants of cancer
progression. Trends Biochem Sci. 40:425–434. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang L, Flygare J, Wong P, Lim B and
Lodish HF: miR-191 regulates mouse erythroblast enucleation by
down-regulating Riok3 and Mxi1. Genes Dev. 25:119–124. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nagpal N and Kulshreshtha R: miR-191: An
emerging player in disease biology. Front Genet. 5:992014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Di Leva G and Croce CM: miRNA profiling of
cancer. Curr Opin Genet Dev. 23:3–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu R, Chen X, Du Y, Yao W, Shen L, Wang
C, Hu Z, Zhuang R, Ning G, Zhang C, et al: Serum microRNA
expression profile as a biomarker in the diagnosis and prognosis of
pancreatic cancer. Clin Chem. 58:610–618. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Collins AL, Wojcik S, Liu J, Frankel WL,
Alder H, Yu L, Schmittgen TD, Croce CM and Bloomston M: A
differential microRNA profile distinguishes cholangiocarcinoma from
pancreatic adenocarcinoma. Ann Surg Oncol. 21:133–138. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nagpal N, Ahmad HM, Chameettachal S,
Sundar D, Ghosh S and Kulshreshtha R: HIF-inducible miR-191
promotes migration in breast cancer through complex regulation of
TGFβ-signaling in hypoxic microenvironment. Sci Rep. 5:96502015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He Y, Cui Y, Wang W, Gu J, Guo S, Ma K and
Luo X: Hypomethylation of the hsa-miR-191 locus causes high
expression of hsa-mir-191 and promotes the
epithelial-to-mesenchymal transition in hepatocellular carcinoma.
Neoplasia. 13:841–853. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song Z, Ren H, Gao S, Zhao X, Zhang H and
Hao J: The clinical significance and regulation mechanism of
hypoxia-inducible factor-1 and miR-191 expression in pancreatic
cancer. Tumor Biol. 35:11319–11328. 2014. View Article : Google Scholar
|
|
22
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Patnaik SK, Kannisto E and Yendamuri S:
Overexpression of microRNA miR-30a or miR-191 in A549 lung cancer
or BEAS-2B normal lung cell lines does not alter phenotype. PloS
One. 5:e92192010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou W, Wang G, Zhao X, Xiong F, Zhou S,
Peng J, Cheng Y, Xu S and Xu X: A multiplex qPCR gene dosage assay
for rapid genotyping and large-scale population screening for
deletional α-thalassemia. J Mol Diagn. 15:642–651. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Markou A, Sourvinou I, Vorkas PA, Yousef
GM and Lianidou E: Clinical evaluation of microRNA expression
profiling in non small cell lung cancer. Lung Cancer. 81:388–396.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nadal E, Chen G, Chang AC, Lin J, Reddy R,
Orringer MB and Beer DG: Ratio of miR-146b/miR-191 in serum
predicts prognosis in surgically resected lung squamous cell
carcinomas. Cancer Res. 72:41472012. View Article : Google Scholar
|
|
27
|
Puisségur MP, Mazure NM, Bertero T,
Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K,
Cardinaud B, Hofman V, et al: miR-210 is overexpressed in late
stages of lung cancer and mediates mitochondrial alterations
associated with modulation of HIF-1 activity. Cell Death Differ.
18:465–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Elson DA, Ryan HE, Snow JW, Johnson R and
Arbeit JM: Coordinate up-regulation of hypoxia inducible factor
(HIF)-1alpha and HIF-1 target genes during multi-stage epidermal
carcinogenesis and wound healing. Cancer Res. 60:6189–6195.
2000.PubMed/NCBI
|
|
29
|
Wang N, Dong CR, Jiang R, Tang C, Yang L,
Jiang QF, Chen GG and Liu ZM: Overexpression of HIF-1α,
metallothionein and SLUG is associated with high TNM stage and
lymph node metastasis in papillary thyroid carcinoma. Int J Clin
Exp Pathol. 7:322–330. 2013.PubMed/NCBI
|
|
30
|
Wu Y, Mao F, Zuo X, Moussalli MJ, Elias E,
Xu W and Shureiqi I: 15-LOX-1 suppression of hypoxia-induced
metastatic phenotype and HIF-1α expression in human colon cancer
cells. Cancer Med. 3:472–484. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu C, Duan P, Li B, Huang C, Jing Y and
Yan W: miR-29a activates Hes1 by targeting Nfia in esophageal
carcinoma cell line TE-1. Oncol Lett. 9:96–102. 2015.PubMed/NCBI
|
|
32
|
Lee JS, Xiao J, Patel P, Schade J, Wang J,
Deneen B, Erdreich-Epstein A and Song HR: A novel tumor-promoting
role for nuclear factor IA in glioblastomas is mediated through
negative regulation of p53, p21, and PAI1. Neuro Oncol. 16:191–203.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song HR, Gonzalez-Gomez I, Suh GS, Commins
DL, Sposto R, Gilles FH, Deneen B and Erdreich-Epstein A: Nuclear
factor IA is expressed in astrocytomas and is associated with
improved survival. Neuro Oncol. 12:122–132. 2010. View Article : Google Scholar : PubMed/NCBI
|
